Clinical Trial Update: A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA). [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and tolerability of nusinersen (ISIS 396443) in participants with spinal muscular atrophy was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• ISIS 396443 (ISIS 396443)
• Nusinersen (nusinersen)

Snippet

Sponsor: Biogen | Conditions: Spinal Muscular Atrophy | Phase 2 | Status: TERMINATED | Results posted: 2020-01-27